Omnix Medical Announces First Patients Dosed in Phase II Trial of Antimicrobial Lead Compound OMN6

Omnix Medical announced that the first patients have been dosed in a Phase II trial of its antimicrobial lead OMN6, marking a key step toward clinical proof-of-concept for the novel agent. OMN6 employs a membrane-disrupting mechanism designed to directly eliminate pathogenic bacteria and is described as a first-in-class treatment for life-threatening, drug-resistant Acinetobacter baumannii infections. The trial is positioned to evaluate OMN6 as a potential first-line therapy, with data advancing toward Phase II clinical proof-of-concept. ClinicalTrials.gov lists the study as NCT06087536. Omnix notes the high unmet medical need and limited options for these infections and outlines next steps toward Phase II readouts.